Finally | 合法藥品大搜索
由NChao著作·2020·被引用4次—Forthepasthalfcentury,wehavebeenattemptingtounderstandgraft-versus-hostdisease(GVHD),attimesrandomlyandmorerecentlyina ...
由 N Chao 著作 · 2020 · 被引用 4 次 — For the past half century, we have been attempting to understand graft-versus-host disease (GVHD), at times randomly and more recently in a ...
Finerenone nejm Nejm GVHD NEJM GVHD nejm Ruxolitinib GVHD Graft versus host disease review Januvia GVHD Acute graft versus host disease biologic process prevention and therapy Finerenone nejm Nejm GVHD NEJM GVHD nejm Ruxolitinib GVHD Graft versus host disease review Januvia GVHD Acute graft versus host disease biologic process prevention and therapy ruxolitinib chronic gvhd Ruxolitinib chronic GVHD Dipeptidyl peptidase 4 inhibition for prophylaxis of acute graft-versus-host disease Ruxolitinib for the treatment of steroid refractory acute gvhd reach1 Jakafi gvhd approval ruxolitinib covid 阿斯匹靈屈臣氏 食品原料廠 novamin副作用 dicyclomine機轉 vancomycin口服泡法 “濟生”安舒麻2%注射劑副作用 Fludiazepam 作用時間 敏使朗錠副作用
Acute Graft | 合法藥品大搜索
由 R Zeiser 著作 · 2017 · 被引用 434 次 — The two main clinical presentations are acute GVHD and chronic GVHD. This review focuses on acute GVHD. Clinical Presentation and Risk Factors. Read More
Sitagliptin to Prevent Acute Graft-versus | 合法藥品大搜索
由 PJ Martin 著作 · 2021 · 被引用 1 次 — Pharmacologic methods to prevent acute graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HSCT) have long ... Read More
Acute Graft-versus | 合法藥品大搜索
2017年11月30日 — The two main clinical presentations are acute GVHD and chronic GVHD. This review focuses on acute GVHD. Clinical Presentation and Risk Factors. Read More
Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft ... | 合法藥品大搜索
由 SS Farag 著作 · 2021 · 被引用 12 次 — Whether inhibition of DPP-4 with sitagliptin may prevent acute GVHD after allogeneic stem-cell transplantation is not known. Read More
Pathophysiology of Chronic Graft | 合法藥品大搜索
由 R Zeiser 著作 · 2017 · 被引用 240 次 — Chronic GVHD, an autoimmune disease that follows allogeneic hematopoietic-cell transplantation, is characterized by infections and ... Read More
Finally | 合法藥品大搜索
由 N Chao 著作 · 2020 · 被引用 4 次 — For the past half century, we have been attempting to understand graft-versus-host disease (GVHD), at times randomly and more recently in a ... Read More
Ruxolitinib for Glucocorticoid | 合法藥品大搜索
由 R Zeiser 著作 · 2020 · 被引用 123 次 — Abstract Background Acute graft-versus-host disease (GVHD) remains a major limitation of allogeneic stem-cell transplantation; ... Read More
Acute Graft-versus | 合法藥品大搜索
2018年2月8日 — To the Editor: In their review of acute graft-versus-host disease (GVHD), Zeiser and Blazar (Nov. 30 issue)1 identify the use of ... Read More
Pathophysiology of Chronic Graft-versus | 合法藥品大搜索
2017年12月28日 — Chronic GVHD, an autoimmune disease that follows allogeneic hematopoietic-cell transplantation, is characterized by infections and ... Read More
Ruxolitinib for Glucocorticoid | 合法藥品大搜索
2021年7月15日 — Abstract Background Chronic graft-versus-host disease (GVHD), a major complication of allogeneic stem-cell transplantation, ... Read More
相關資訊整理
【捷可衛錠 5毫克】1.適用於治療中度風險或高風險之骨髓纖維化,包括原發性骨髓纖維化、真性紅血球增多症後骨髓纖維化、或血小板增多症後骨髓纖維化。2.適用於接受hydroxyurea 治療後有抗藥性或無耐受性的真性紅血球增多症。
藥品名稱:捷可衛錠5毫克許可證字號:衛部藥輸字第026359號許可證種類:製 劑適應症:1.適用於治療中度風險或高風險之骨髓纖維...
【捷可衛錠 15毫克】1.適用於治療中度風險或高風險之骨髓纖維化,包括原發性骨髓纖維化、真性紅血球增多症後骨髓纖維化、或血小板增多症後骨髓纖維化。2.適用於接受hydroxyurea 治療後有抗藥性或無耐受性的真性紅血球增多症。
藥品名稱:捷可衛錠15毫克許可證字號:衛部藥輸字第026360號許可證種類:製 劑適應症:1.適用於治療中度風險或高風險之骨髓纖維...
【捷可衛錠 20毫克】1.適用於治療中度風險或高風險之骨髓纖維化,包括原發性骨髓纖維化、真性紅血球增多症後骨髓纖維化、或血小板增多症後骨髓纖維化。2.適用於接受hydroxyurea 治療後有抗藥性或無耐受性的真性紅血球增多症。
藥品名稱:捷可衛錠20毫克許可證字號:衛部藥輸字第026361號許可證種類:製 劑適應症:1.適用於治療中度風險或高風險之骨髓纖維...
【捷可衛錠 10毫克】1.適用於治療中度風險或高風險之骨髓纖維化,包括原發性骨髓纖維化、真性紅血球增多症後骨髓纖維化、或血小板增多症後骨髓纖維化。2.適用於接受hydroxyurea 治療後有抗藥性或無耐受性的真性紅血球增多症。
藥品名稱:捷可衛錠10毫克許可證字號:衛部藥輸字第026707號許可證種類:製 劑適應症:1.適用於治療中度風險或高風險之骨髓纖維...